STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Drug Design & Discovery Review Article

Novel 1,3,4-Thiadiazole Derivatives: Design, Synthesis, Characterization and Anticancer Evaluation – A Review

  1. Mane Yogita L Department of Pharmacy, Dattakala College of Pharmacy, Pune
  2. Vishal Babar Department of Pharmacy, Dattakala College of Pharmacy, Pune
  3. Sudarshan Nagrale Department of Pharmacy, Dattakala College of Pharmacy, Pune

Abstract

Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The clinical usefulness of many anticancer drugs is often restricted by toxicity, poor selectivity, and the emergence of drug resistance. These limitations have encouraged the search for novel heterocyclic compounds with improved therapeutic efficacy and safety. Among these, the 1,3,4-thiadiazole scaffold has gained considerable attention because of its favorable physicochemical characteristics, metabolic stability, and ability to interact with multiple biological targets. Various 1,3,4-thiadiazole derivatives have demonstrated potent anticancer activity by inducing apoptosis, arresting the cell cycle, inhibiting angiogenesis, and modulating important signaling pathways involved in tumor progression. Structural modification and molecular hybridization have further enhanced their pharmacological potential. This review summarizes recent advances in the chemistry, design strategies, synthetic approaches, structure–activity relationships, and anticancer applications of 1,3,4-thiadiazole derivatives. In addition, current challenges and future perspectives associated with the development of thiadiazole-based anticancer agents are briefly discussed.

Keywords

References (20)

  1. Indelicato S, Bongiorno D, Mauro M, Cascioferro S. Recent Developments of 1,3,4-Thiadiazole Compounds as Anticancer Agents. Pharmaceuticals. 2025;18(4):580. doi:10.3390/ph18040580
  2. Janowska S, Paneth A, Wujec M. Cytotoxic Properties of 1,3,4-Thiadiazole Derivatives--A Review. Molecules. 2020;25(18):4309. doi: 10.33907 molecules25184309.
  3. Jampilek J. Heterocycles in Medicinal Chemistry. Molecules. 2019;24(21):3839. doi:10.3390/molecules24213839
  4. LiY, Geng I, Liu Y., Yu S., Zhao G. Thiadiazole --A Promising Structure in Medicinal Chemistry. ChemMedChem. 2013:8:27-41. Doi: 10.1002 cmdc.201200355.
  5. Kumar D., Kumar H., Kumar V., Deep A., Sharma A. Marwaha M.G. Marwaha R.K Mechanism-Based Approaches of 1,3,4 Thiadiazole Scaffolds as Potent Enzyme Inhibitors for Cytotoxicity and Antiviral Activity. Med. Drug Discov. 2023; 17:100150. doi:10.1016/i.medidd.2022.100150
  6. El-Masry RM, Essa BM, Selim AA, El-Emam SZ, Mohamed KO, Sakr TM, et al. New 5-Aryl-1,3,4-Thiadiazole-Based Anticancer Agents: Design, Synthesis, In Vitro Biological Evaluation and In Vivo Radioactive Tracing Studies. Pharmaceuticals. 2022;15(12):1476. doi:10.3390/ph15121476
  7. Abouzied AS, Al-Humaidi JY, Bazaid AS, Qanash H, Binsaleh NK, Alamri A, et al. Synthesis, Molecular Docking Study, and Cytotoxicity Evaluation of Some Novel 1,3,4-Thiadiazole as Well as 1,3-Thiazole Derivatives Bearing a Pyridine Moiety. Molecules. 2022;27(19):6368. doi:10.3390/molecules27196368
  8. Alsehli M, Aljuhani A, Ihmaid SK, El-Messery SM, Othman DIA, El-Sayed AAAA, et al. Design and Synthesis of Benzene Homologues Tethered with 1,2,4-Triazole and 1,3,4-Thiadiazole Motifs Revealing Dual MCF-7/HepG2 Cytotoxic Activity with Prominent Selectivity via Histone Demethylase LSD1 Inhibitory Effect. International Journal of Molecular Sciences. 2022;23(15):8796. doi:10.3390/ijms23158796
  9. Kang JX, Li C, Cheng YM, Huang M, Zhao GK, Jin ZL, et al. Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents. Current Medicinal Chemistry. 2025;32(25):5180-5225. doi:10.2174/0109298673308896240528173317
  10. Li XY, Wang DP, Li S, Xue WH, Qian XH, Liu KL, et al. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis. Bioorganic Chemistry. 2022;119:105469. doi:10.1016/j.bioorg.2021.105469
  11. Serag M.l., Tawfik S.S., Eisa H.M., Badr S.M.I Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4- Thiadiazole-Based Compounds as EGFR Inhibitors. Drug Dev. Res. 2025;86: e70035. doi 10.1002, ddr.70035.
  12. Hekal M.H., Farag P.S., Hemdan M.M. El- Saved A.A., Hassaballah A.1., El- Saved W.M. New 1,3,4-Thiadiazoles as Potential Anticancer Agents: Pro- Apoptotic, Cell Cycle Arrest, Molecular Modelling, and ADMET Profile. RSC Adv. 2023:13:1581015825. doi:
  13. 1039/D3RA02716C.
  14. Żurawska K, Stokowy M, Kapica P, Olesiejuk M, Kudelko A, Papaj K, et al. Synthesis and Preliminary Anticancer Activity Assessment of N-Glycosides of 2-Amino-1,3,4-thiadiazoles. Molecules. 2021;26(23):7245. doi:10.3390/molecules26237245
  15. Stecoza C.E. Nitulescu G.M. Draghici C. Caproiu M.T., Hanganu A., Olaru O.T., Mihai D.P., Bostan M. Mihaila M. Synthesis of 1,3,4- Thiadiazole Derivatives and Their Anticancer Evaluation. Int. J. Mol. Sci. 2023; 24:17476. doi: 10.3390 ijms242417476.
  16. Janowska S. Khylyuk D., Bielawska A. Szymanowska A., Gornowicz A., Bielawski K. Noworól J., Mandziuk S., Wujec M. New 1,3,4- Thiadiazole Derivatives with Anticancer Activity. Molecules. 2022: 27:1814. doi: 10.3390 molecules2706 1814.
  17. Oubella A., Bimoussa A., Rehman M.T. AlAjmi M.F., Auhmani A., Taha M.L. Morjani H. Itto M.Y.A. Molecular Hybrids Based on 1,2,3- Triazole and 1,3,4- Thiadiazole Cores: Synthesis, Characterization, Anticancer Activity and in Silico Study. J. Mol. Struct. 2024; 13 11:138339. doi: 10.10167 j. molstruc.2024.138339.
  18. Cascioferro S. Li Petri G. Parrino B. El Hassouni B. Carbone D. Arizza V. Perricone U. Padova A. Funel N. Peters G.J., et al. 3-(6- Phenylimidazo [2, 1-b] [1,3,4] Thiadiazole-2-Y1)-1H- Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Molecules 2020:25:329. doi:
  19. 3390/molecules25020329
  20. Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1120911
Support